Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 11/20 | 0.50 |
| ▸ | MEF2D | Q14814 | 11/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221179 | 0.89 | HDAC4 (0.54) | HDAC4MEF2DSIRT2SIRT1EP300 | |
| SCHEMBL21221186 | 0.89 | HDAC4 (0.54) | HDAC4MEF2DSIRT2SIRT1EP300 | |
| SCHEMBL21221170 | 0.88 | HDAC4 (0.49) | HDAC4MEF2DEP300 | |
| SCHEMBL18490884 | 0.82 | KLK7 (0.58) | SIRT2SIRT1SYKSIRT3KLK7 | |
| SCHEMBL21221196 | 0.81 | SIRT2 (0.56) | SIRT2SIRT1HDAC1SIRT3 | |
| SCHEMBL21221198 | 0.81 | SIRT2 (0.56) | SIRT2SIRT1HDAC1SIRT3 | |
| SCHEMBL21221195 | 0.80 | HDAC4 (0.48) | HDAC4MEF2DHDAC1EP300 | |
| SCHEMBL23056529 | 0.80 | CTSK (0.48) | SYKKLK7KLK5 | |
| SCHEMBL4934327 | 0.80 | CTSL (0.49) | SYKKLK7KLK5 | |
| SCHEMBL4936015 | 0.80 | BCHE (0.51) | SIRT2SIRT1SIRT3KLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | STANDARD LLC | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | MEF2D, MYLK2, TNNT2 | HDAC4 81/4885MEF2D 1/4885SIRT2 383/4885 |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | MEF2D, MYLK2, MYOF | HDAC4 97/4885MEF2D 1/4885SIRT2 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.